The federal government can't require AstraZeneca to change its policy on lowering drug prices for certain pharmacies used by health care facilities with low-income patients, a District of Delaware court determined Wednesday.

The opinion written by U.S. District Judge Leonard P. Stark remands a letter of violation in which the Health Resources and Services Administration claimed the drug manufacturer is legally held to charging lowered prices at any pharmacy contracted by an entity covered under the 340B Program.